Dr. Swaminathan is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
The University of Texas MD Anderson Cancer Center
1515 Holcombe Blvd
Houston, TX 77030- Is this information wrong?
Education & Training
- University at BuffaloFellowship, Hematology and Medical Oncology, 2019 - 2022
- Carle Foundation HospitalResidency, Internal Medicine, 2014 - 2017
- OtherClass of 2012
Certifications & Licensure
- TX State Medical License 2017 - 2026
- NY State Medical License 2019 - 2022
- IL State Medical License 2014 - 2017
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- 1 citationsA multicenter study of venetoclax-based treatment for patients with Richter transformation of chronic lymphocytic leukemia.Saad S Kenderian, Mahesh Swaminathan, Erin M Parry, Jan A Burger, Matthew S Davids, Alessandra Ferrajoli, Nitin Jain, Yucai Wang, William G Wierda, Jennifer A Woyach, ...> ;Blood Advances. 2024 May 28
- 2 citationsOral decitabine plus cedazuridine and venetoclax in patients with higher-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia: a single-centre, phase 1/2...Bataller, A., Montalban-Bravo, G., Bazinet, A., Alvarado, Y., Chien, K., Venugopal, S., Ishizawa, J., Hammond, D., Swaminathan, M., Sasaki, K., Issa, G., Short, N., Ma...> ;The Lancet. Haematology. 2024 Mar 1
- Can measurable residual disease assessment be reliably used to defer allogeneic stem cell transplant in patients with intermediate-risk acute myeloid leukemia?Mahesh Swaminathan, Farhad Ravandi> ;Haematologica. 2023 Oct 1
- Join now to see all
Authored Content
- The Combination of Quizartinib with Azacitidine or Low Dose Cytarabine Is Highly Active in Patients (Pts) with FLT3-ITD Mutated Myeloid Leukemias: Interim Report of a Phase I/II TrialOctober 2017
Hospital Affiliations
- University of Texas M.D. Anderson Cancer CenterHouston, Texas
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: